Adicet Bio
ACET
53 hedge funds and large institutions have $266M invested in Adicet Bio in 2021 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 21 increasing their positions, 8 reducing their positions, and 7 closing their positions.
163% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 8
129% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 7
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
99% more capital invested
Capital invested by funds: $134M → $266M (+$132M)
20% more funds holding
Funds holding: 44 → 53 (+9)
1% more ownership
Funds ownership: 3.04% → 4.04% (+1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$32M |
| 2 |
A
Abingworth
London,
United Kingdom
|
+$23.2M |
| 3 |
CCM
Consonance Capital Management
New York
|
+$17.5M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$15M |
| 5 |
VA
VR Adviser
New York
|
+$14.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$1.82M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
-$562K |
| 3 |
6CM
683 Capital Management
New York
|
-$362K |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$349K |
| 5 |
Morgan Stanley
New York
|
-$220K |
ACET Hedge Fund Activity: Q1 2021 in Review
53 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Adicet Bio (ACET) for Q1 2021, worth a combined $266M — up 99% from $134M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new ACET positions and 7 closed out — a net gain of 9 holders — while 21 added to existing stakes and 8 trimmed.
The largest buyer was Avidity Partners Management, opening a new position worth an estimated $32M. The largest seller was Artal Group, exiting entirely with an estimated $1.82M sold.
- 53 institutional investors held Adicet Bio (ACET) as of Q1 2021, up from 44 in Q4 2020.
- Funds reported $266M of Adicet Bio stock for Q1 2021, up 99% quarter-over-quarter.
- 16 funds opened new Adicet Bio positions in Q1 2021 and 7 closed out, a net change of +9 holders.
- The largest Adicet Bio buyer in Q1 2021 was Avidity Partners Management, an estimated $32M added.
- The largest Adicet Bio seller in Q1 2021 was Artal Group, an estimated $1.82M sold.
Based on aggregated 13F filings for Q1 2021.